KPIs & Operating Metrics(New)
Aesthetics Revenue By CategoryAesthetics Revenue By Category AnnualAesthetics Revenue By GeographyAesthetics Revenue By Geography AnnualBreakdown Of AssetsEmployee StatisticsEye Care Revenue By CategoryEye Care Revenue By Category AnnualEye Care Revenue By GeographyEye Care Revenue By Geography AnnualGross MarginGross Margin %Gross Margin AnnualGross Margin Annual %Hematology Oncology Revenue By CategoryHematology Oncology Revenue By Category AnnualHematology Oncology Revenue By GeographyHematology Oncology Revenue By Geography AnnualImmunology Revenue By CategoryImmunology Revenue By Category AnnualImmunology Revenue By GeographyImmunology Revenue By Geography AnnualIncome Before Income Taxes By RegionLong Lived Assets By RegionNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNeuroscience Revenue By GeographyNeuroscience Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX SegregationOther Key Products Revenue By CategoryOther Key Products Revenue By Category AnnualOther Key Products Revenue By GeographyOther Key Products Revenue By Geography AnnualProperty & Equipment BreakdownRevenueRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Ship To LocationRevenue By Ship To Location %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Revenue (2016 - 2025)

Historic Revenue for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $15.8 billion.

  • AbbVie's Revenue rose 910.1% to $15.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 billion, marking a year-over-year increase of 740.28%. This contributed to the annual value of $56.3 billion for FY2024, which is 371.15% up from last year.
  • Latest data reveals that AbbVie reported Revenue of $15.8 billion as of Q3 2025, which was up 910.1% from $15.4 billion recorded in Q2 2025.
  • AbbVie's Revenue's 5-year high stood at $15.8 billion during Q3 2025, with a 5-year trough of $12.2 billion in Q1 2023.
  • Moreover, its 5-year median value for Revenue was $14.3 billion (2021), whereas its average is $14.2 billion.
  • In the last 5 years, AbbVie's Revenue surged by 5094.56% in 2021 and then plummeted by 969.86% in 2023.
  • Quarter analysis of 5 years shows AbbVie's Revenue stood at $14.9 billion in 2021, then rose by 1.58% to $15.1 billion in 2022, then dropped by 5.42% to $14.3 billion in 2023, then increased by 5.6% to $15.1 billion in 2024, then grew by 4.46% to $15.8 billion in 2025.
  • Its Revenue stands at $15.8 billion for Q3 2025, versus $15.4 billion for Q2 2025 and $13.3 billion for Q1 2025.